JP2019537602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537602A5 JP2019537602A5 JP2019523810A JP2019523810A JP2019537602A5 JP 2019537602 A5 JP2019537602 A5 JP 2019537602A5 JP 2019523810 A JP2019523810 A JP 2019523810A JP 2019523810 A JP2019523810 A JP 2019523810A JP 2019537602 A5 JP2019537602 A5 JP 2019537602A5
- Authority
- JP
- Japan
- Prior art keywords
- xanthene
- methyl
- oxy
- alkylene
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002947 alkylene group Chemical group 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 19
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- -1 SCHR 6 Inorganic materials 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- YQHJSHUOKMQLOP-UHFFFAOYSA-N 1-[3-[5-[2-(dimethylamino)ethoxy]-7-methyl-9-oxoxanthen-3-yl]oxyphenyl]-3-phenylurea Chemical compound CN(CCOC1=C2OC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=C(C=CC=1)NC(=O)NC1=CC=CC=C1)C YQHJSHUOKMQLOP-UHFFFAOYSA-N 0.000 claims 1
- JUOWDPFSSPMSSN-UHFFFAOYSA-N 1-[3-[5-[3-(dimethylamino)propoxy]-7-methyl-9-oxoxanthen-3-yl]oxyphenyl]-3-phenylurea Chemical compound CN(CCCOC1=C2OC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=C(C=CC=1)NC(=O)NC1=CC=CC=C1)C JUOWDPFSSPMSSN-UHFFFAOYSA-N 0.000 claims 1
- LWQJMJGSIVBADS-UHFFFAOYSA-N 10-[3-(dimethylamino)propyl]-2-methyl-6-phenylsulfanylacridin-9-one Chemical compound CN(CCCN1C=2C=CC(=CC=2C(C2=CC=C(C=C12)SC1=CC=CC=C1)=O)C)C LWQJMJGSIVBADS-UHFFFAOYSA-N 0.000 claims 1
- YAGRAWDBWZRWJI-UHFFFAOYSA-N 2-chloro-4-[2-(dimethylamino)ethoxy]-6-[6-[2-(4-methoxyphenyl)ethyl]pyridin-3-yl]oxyxanthen-9-one Chemical compound ClC1=CC=2C(C3=CC=C(C=C3OC=2C(=C1)OCCN(C)C)OC=1C=NC(=CC=1)CCC1=CC=C(C=C1)OC)=O YAGRAWDBWZRWJI-UHFFFAOYSA-N 0.000 claims 1
- UBBAGSRRISOVDP-UHFFFAOYSA-N 2-chloro-4-[2-(dimethylamino)ethoxy]-6-phenoxyxanthen-9-one Chemical compound ClC1=CC=2C(C3=CC=C(C=C3OC=2C(=C1)OCCN(C)C)OC1=CC=CC=C1)=O UBBAGSRRISOVDP-UHFFFAOYSA-N 0.000 claims 1
- HYIATFCHLMFPKX-UHFFFAOYSA-N 2-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-phenoxyxanthen-9-one Chemical compound CC1=CC=2C(C3=CC=C(C=C3OC=2C(=C1)OCC1CCN(CC1)C)OC1=CC=CC=C1)=O HYIATFCHLMFPKX-UHFFFAOYSA-N 0.000 claims 1
- IMJOKQWEHUYQTE-UHFFFAOYSA-N 2-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-phenoxyxanthen-9-one Chemical compound CC1=CC=2C(C3=CC=C(C=C3OC=2C(=C1)OCCC1CCN(CC1)C)OC1=CC=CC=C1)=O IMJOKQWEHUYQTE-UHFFFAOYSA-N 0.000 claims 1
- ILNGJMYEBIKSTI-UHFFFAOYSA-N 3-[5-[2-(dimethylamino)ethoxy]-7-methyl-9-oxothioxanthen-3-yl]oxy-N-phenylbenzamide Chemical compound CN(CCOC1=C2SC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1)C ILNGJMYEBIKSTI-UHFFFAOYSA-N 0.000 claims 1
- IJLCLWPXHCLWKX-UHFFFAOYSA-N 3-[5-[2-(dimethylamino)ethoxy]-7-methyl-9-oxoxanthen-3-yl]oxy-N-phenylbenzamide Chemical compound CN(CCOC1=C2OC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1)C IJLCLWPXHCLWKX-UHFFFAOYSA-N 0.000 claims 1
- OUAYMQRYEPUGPW-UHFFFAOYSA-N 3-[5-[2-(dimethylamino)ethoxy]-9-oxoxanthen-3-yl]oxy-N-phenylbenzamide Chemical compound CN(CCOC1=C2OC=3C=C(C=CC=3C(C2=CC=C1)=O)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1)C OUAYMQRYEPUGPW-UHFFFAOYSA-N 0.000 claims 1
- VXZAWULSRVYKGZ-UHFFFAOYSA-N 3-[5-[3-(dimethylamino)propoxy]-7-methyl-9-oxoxanthen-3-yl]oxy-N-phenylbenzamide Chemical compound CN(CCCOC1=C2OC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1)C VXZAWULSRVYKGZ-UHFFFAOYSA-N 0.000 claims 1
- LPSUGVBAQYOYHK-UHFFFAOYSA-N 3-[5-[5-(2-aminoethoxy)-7-methyl-9-oxoxanthen-3-yl]oxypyridin-2-yl]-N-cyclopentylpropanamide Chemical compound NCCOC1=C2OC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=CC(=NC=1)CCC(=O)NC1CCCC1 LPSUGVBAQYOYHK-UHFFFAOYSA-N 0.000 claims 1
- WKWOBAXHMFHPKC-UHFFFAOYSA-N 3-[5-[7-bromo-5-[2-(dimethylamino)ethoxy]-9-oxoxanthen-3-yl]oxypyridin-2-yl]-N-cyclopentylpropanamide Chemical compound BrC1=CC(=C2OC=3C=C(C=CC=3C(C2=C1)=O)OC=1C=CC(=NC=1)CCC(=O)NC1CCCC1)OCCN(C)C WKWOBAXHMFHPKC-UHFFFAOYSA-N 0.000 claims 1
- JYHOFOGQJGMQOH-UHFFFAOYSA-N 3-[7-chloro-5-[2-(dimethylamino)ethoxy]-9-oxoxanthen-3-yl]oxy-N-phenylbenzamide Chemical compound ClC1=CC(=C2OC=3C=C(C=CC=3C(C2=C1)=O)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1)OCCN(C)C JYHOFOGQJGMQOH-UHFFFAOYSA-N 0.000 claims 1
- DHZYEEDRNNYUHV-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-[6-(3-morpholin-4-yl-3-oxopropyl)pyridin-3-yl]oxyxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)CCC(=O)N1CCOCC1)=O)C)C DHZYEEDRNNYUHV-UHFFFAOYSA-N 0.000 claims 1
- JKYIPVBUQVHVTM-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-[6-(3-oxo-3-pyrrolidin-1-ylpropyl)pyridin-3-yl]oxyxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)CCC(N1CCCC1)=O)=O)C)C JKYIPVBUQVHVTM-UHFFFAOYSA-N 0.000 claims 1
- PHXCGPSZGOZHLH-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-[6-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]pyridin-3-yl]oxyxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)CCC(=O)N1CCN(CC1)C)=O)C)C PHXCGPSZGOZHLH-UHFFFAOYSA-N 0.000 claims 1
- FFXBPFWXEHSCKF-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-[6-[[4-(trifluoromethoxy)phenyl]methylamino]pyridin-3-yl]oxyxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)NCC1=CC=C(C=C1)OC(F)(F)F)=O)C)C FFXBPFWXEHSCKF-UHFFFAOYSA-N 0.000 claims 1
- OTJAOVKRLINQNF-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-[6-[[6-(trifluoromethyl)pyridin-3-yl]methoxy]pyridin-3-yl]oxyxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)OCC=1C=NC(=CC=1)C(F)(F)F)=O)C)C OTJAOVKRLINQNF-UHFFFAOYSA-N 0.000 claims 1
- SLCMYYNYJQIDFS-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-phenoxythioxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3SC1=2)OC1=CC=CC=C1)=O)C)C SLCMYYNYJQIDFS-UHFFFAOYSA-N 0.000 claims 1
- FXDMRSZDOHGDRH-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-phenoxyxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC1=CC=CC=C1)=O)C)C FXDMRSZDOHGDRH-UHFFFAOYSA-N 0.000 claims 1
- JVHRIEPTXXUJKJ-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-2-methyl-6-pyridin-3-yloxyxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC=CC=1)=O)C)C JVHRIEPTXXUJKJ-UHFFFAOYSA-N 0.000 claims 1
- DPIVWXZHWLQDPM-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-(6-methoxypyridin-3-yl)oxy-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)OC)=O)C)C DPIVWXZHWLQDPM-UHFFFAOYSA-N 0.000 claims 1
- CBFHWSCSSLAZDZ-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[(6-methoxypyridin-3-yl)methyl]-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)CC=1C=NC(=CC=1)OC)=O)C)C CBFHWSCSSLAZDZ-UHFFFAOYSA-N 0.000 claims 1
- NDLVLFLBOJFAIN-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[3-methoxy-4-[(4-methylphenyl)methoxy]phenoxy]-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC1=CC(=C(C=C1)OCC1=CC=C(C=C1)C)OC)=O)C)C NDLVLFLBOJFAIN-UHFFFAOYSA-N 0.000 claims 1
- ZVWKPCFROJVJFJ-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[5-methoxy-6-[(4-methoxyphenyl)methoxy]pyridin-3-yl]oxy-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=C(C=1)OC)OCC1=CC=C(C=C1)OC)=O)C)C ZVWKPCFROJVJFJ-UHFFFAOYSA-N 0.000 claims 1
- WOEGFFPHDLXDPM-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[6-[(4-methoxyphenyl)methoxy]pyridin-3-yl]oxy-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)OCC1=CC=C(C=C1)OC)=O)C)C WOEGFFPHDLXDPM-UHFFFAOYSA-N 0.000 claims 1
- IKEVSKMKKGAKEH-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[6-[(4-methoxyphenyl)methylamino]pyridin-3-yl]oxy-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)NCC1=CC=C(C=C1)OC)=O)C)C IKEVSKMKKGAKEH-UHFFFAOYSA-N 0.000 claims 1
- ZJLXIZZIADJDJK-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[6-[(6-methoxypyridin-3-yl)methoxy]pyridin-3-yl]oxy-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)OCC=1C=NC(=CC=1)OC)=O)C)C ZJLXIZZIADJDJK-UHFFFAOYSA-N 0.000 claims 1
- IXHFSJWDEJZPDZ-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[6-[(6-methoxypyridin-3-yl)methylamino]pyridin-3-yl]oxy-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)NCC=1C=NC(=CC=1)OC)=O)C)C IXHFSJWDEJZPDZ-UHFFFAOYSA-N 0.000 claims 1
- SLJZVWMBPWRVIW-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[6-[2-(4-methoxyphenyl)ethyl]pyridin-3-yl]oxy-2-methylthioxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3SC1=2)OC=1C=NC(=CC=1)CCC1=CC=C(C=C1)OC)=O)C)C SLJZVWMBPWRVIW-UHFFFAOYSA-N 0.000 claims 1
- PGGPWGIODAFXFU-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]-6-[6-[2-(4-methoxyphenyl)ethyl]pyridin-3-yl]oxy-2-methylxanthen-9-one Chemical compound CN(CCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC=1C=NC(=CC=1)CCC1=CC=C(C=C1)OC)=O)C)C PGGPWGIODAFXFU-UHFFFAOYSA-N 0.000 claims 1
- HVPWCRDDMSSZHB-UHFFFAOYSA-N 4-[3-(dimethylamino)propoxy]-2-methyl-6-phenoxyxanthen-9-one Chemical compound CN(CCCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC1=CC=CC=C1)=O)C)C HVPWCRDDMSSZHB-UHFFFAOYSA-N 0.000 claims 1
- PHLCRYGAXSEGPS-UHFFFAOYSA-N 4-[4-(dimethylamino)butoxy]-2-methyl-6-phenoxyxanthen-9-one Chemical compound CN(CCCCOC1=CC(=CC=2C(C3=CC=C(C=C3OC1=2)OC1=CC=CC=C1)=O)C)C PHLCRYGAXSEGPS-UHFFFAOYSA-N 0.000 claims 1
- KVSYUBDIZSCHJD-UHFFFAOYSA-N 5-[2-(dimethylamino)ethoxy]-3-[6-[2-(4-methoxyphenyl)ethyl]pyridin-3-yl]oxyxanthen-9-one Chemical compound CN(CCOC1=C2OC=3C=C(C=CC=3C(C2=CC=C1)=O)OC=1C=NC(=CC=1)CCC1=CC=C(C=C1)OC)C KVSYUBDIZSCHJD-UHFFFAOYSA-N 0.000 claims 1
- DMUKONPKIVWWDO-UHFFFAOYSA-N 5-[2-(dimethylamino)ethoxy]-3-phenoxyxanthen-9-one Chemical compound CN(CCOC1=C2OC=3C=C(C=CC=3C(C2=CC=C1)=O)OC1=CC=CC=C1)C DMUKONPKIVWWDO-UHFFFAOYSA-N 0.000 claims 1
- RAMMLFKSSRNPPA-UHFFFAOYSA-N 6-(5,6-dimethoxypyridin-3-yl)oxy-4-[2-(dimethylamino)ethoxy]-2-methylxanthen-9-one Chemical compound COC=1C=C(C=NC=1OC)OC=1C=C2OC=3C(=CC(=CC=3C(C2=CC=1)=O)C)OCCN(C)C RAMMLFKSSRNPPA-UHFFFAOYSA-N 0.000 claims 1
- HEOWUXJPJPVNGF-UHFFFAOYSA-N 6-(6-aminopyridin-3-yl)oxy-4-[2-(dimethylamino)ethoxy]-2-methylxanthen-9-one Chemical compound NC1=CC=C(C=N1)OC=1C=C2OC=3C(=CC(=CC=3C(C2=CC=1)=O)C)OCCN(C)C HEOWUXJPJPVNGF-UHFFFAOYSA-N 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- WJTUQNTUXQDXPP-UHFFFAOYSA-N N-[2-[5-[5-[2-(dimethylamino)ethoxy]-7-methyl-9-oxoxanthen-3-yl]oxypyridin-2-yl]ethyl]cyclopentanecarboxamide Chemical compound CN(CCOC1=C2OC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=CC(=NC=1)CCNC(=O)C1CCCC1)C WJTUQNTUXQDXPP-UHFFFAOYSA-N 0.000 claims 1
- HAYGUZANMRUXFM-UHFFFAOYSA-N N-[2-[5-[5-[2-(dimethylamino)ethoxy]-7-methyl-9-oxoxanthen-3-yl]oxypyridin-2-yl]ethyl]pyrrolidine-1-carboxamide Chemical compound CN(CCOC1=C2OC=3C=C(C=CC=3C(C2=CC(=C1)C)=O)OC=1C=CC(=NC=1)CCNC(=O)N1CCCC1)C HAYGUZANMRUXFM-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 C[*-]C*c(cc(*)cc12)c1Sc(cc(**)cc1)c1C2=O Chemical compound C[*-]C*c(cc(*)cc12)c1Sc(cc(**)cc1)c1C2=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ72576716 | 2016-11-04 | ||
| NZ725767 | 2016-11-04 | ||
| PCT/IB2017/056848 WO2018083635A2 (en) | 2016-11-04 | 2017-11-03 | Tricyclic heterocyclic derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537602A JP2019537602A (ja) | 2019-12-26 |
| JP2019537602A5 true JP2019537602A5 (enExample) | 2020-12-10 |
| JP7096817B2 JP7096817B2 (ja) | 2022-07-06 |
Family
ID=62075593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523810A Active JP7096817B2 (ja) | 2016-11-04 | 2017-11-03 | 三環式複素環式誘導体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11028064B2 (enExample) |
| EP (1) | EP3535243B1 (enExample) |
| JP (1) | JP7096817B2 (enExample) |
| CN (1) | CN110139852A (enExample) |
| AU (1) | AU2017355603A1 (enExample) |
| WO (1) | WO2018083635A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102240821B1 (ko) * | 2017-03-13 | 2021-04-15 | 광주과학기술원 | Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 5-히드록시 피리딘계 화합물 및 이를 포함하는 약학적 조성물 |
| CN108976164A (zh) * | 2018-06-20 | 2018-12-11 | 南通常佑药业科技有限公司 | 手性哌啶胺化合物的制备方法及手性拆分剂的回收套用方法 |
| WO2021101521A1 (en) * | 2019-11-19 | 2021-05-27 | Provecetus Pharmatech, Inc. | Composition and method for treating hematologic cancers |
| BR112023004719A2 (pt) * | 2020-09-21 | 2023-04-18 | Hutchison Medipharma Ltd | Compostos heteroaromáticos e usos dos mesmos |
| CN114890899B (zh) * | 2022-04-02 | 2023-10-03 | 南京农业大学 | 一种制备二苯醚酯类化合物的方法 |
| CN115557890B (zh) * | 2022-09-01 | 2024-06-25 | 宁波大学 | 一种多取代吖啶酮烷基衍生物及其制备方法和用途 |
| IT202200024963A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1192651A (en) * | 1968-01-09 | 1970-05-20 | Sterling Drug Inc | Xanthene Derivatives |
| BE759292A (fr) | 1969-11-27 | 1971-05-24 | Allen & Hanburys Ltd | Derives de xanthone, leur preparation et leur emploi |
| US3859286A (en) * | 1970-12-11 | 1975-01-07 | Richardson Merrell Inc | Bis-basic ketones of xanthene and xanthen-9-one |
| EP0278176B1 (en) | 1986-12-23 | 1994-03-09 | Warner-Lambert Company | Compounds having antitumour and antibacterial properties |
| AU2002367773A1 (en) | 2001-04-06 | 2003-11-03 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| JP4654035B2 (ja) | 2002-11-05 | 2011-03-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗菌剤 |
| WO2005003131A1 (en) | 2003-06-27 | 2005-01-13 | Janssen Pharmaceutica N.V. | Tricyclic delta opioid modulators |
| AU2005335481A1 (en) | 2004-08-05 | 2007-04-19 | Janssen Pharmaceutica N.V. | Tricyclic delta- opioid modulators |
| WO2006044707A1 (en) | 2004-10-13 | 2006-04-27 | Smithkline Beecham Corporation | Chemical compounds |
| PE20080359A1 (es) | 2006-04-19 | 2008-06-06 | Novartis Ag | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r |
| WO2008016661A2 (en) * | 2006-08-02 | 2008-02-07 | Xanthus Pharmaceuticals, Inc. | Morpholino compounds for treating inflammatory and demyelinating diseases and cancers |
| WO2008048117A2 (en) | 2006-10-17 | 2008-04-24 | Auckland Uniservices Limited | Synthesis of 5,6-dimethyl-9-oxo-9h-xanthen-4-yl- acetic acid (dmxaa) |
| AU2007309279B2 (en) | 2006-10-20 | 2011-03-24 | Irm Llc | Compositions and methods for modulating c-kit and PDGFR receptors |
| CN101195609B (zh) | 2007-09-28 | 2011-04-20 | 武汉远大制药集团有限公司 | 5,6-二甲基呫吨酮-4-乙酸的制备方法及由此方法制备的衍生物和药物制剂 |
| DE102007047495B4 (de) | 2007-10-04 | 2009-07-16 | Contitech Kühner Gmbh & Cie. Kg | Wellrohrschlauchleitung sowie Verfahren zu deren Herstellung |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| CN101279967B (zh) | 2008-05-29 | 2010-11-10 | 武汉远大制药集团有限公司 | 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途 |
| AR072295A1 (es) | 2008-06-26 | 2010-08-18 | Novartis Ag | Metodo de preparacion del acio 5,6-dimetil-9-oxo-9h-xanten-4-il-acetico |
| US20110201678A1 (en) | 2008-10-17 | 2011-08-18 | Masse Craig E | Xanthenone-4-Acetic Acid Derivatives |
| AU2010295622A1 (en) * | 2009-09-16 | 2012-05-10 | Cylene Pharmaceuticals, Inc. | Tricyclic compounds and pharmaceutical uses thereof |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| UA108222C2 (xx) | 2009-12-21 | 2015-04-10 | СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS | |
| TWI414520B (zh) | 2010-10-06 | 2013-11-11 | Nat Defense Medical Ct | 噻噸酮衍生物 |
| PH12013501221A1 (en) | 2010-12-13 | 2022-03-30 | Array Biopharma Inc | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| EP2791143B1 (en) | 2011-12-15 | 2016-02-24 | Bayer Intellectual Property GmbH | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer |
| GB2498976A (en) | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2842937B1 (en) | 2012-04-23 | 2018-01-17 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
-
2017
- 2017-11-03 JP JP2019523810A patent/JP7096817B2/ja active Active
- 2017-11-03 WO PCT/IB2017/056848 patent/WO2018083635A2/en not_active Ceased
- 2017-11-03 US US16/347,420 patent/US11028064B2/en active Active
- 2017-11-03 CN CN201780082274.1A patent/CN110139852A/zh active Pending
- 2017-11-03 AU AU2017355603A patent/AU2017355603A1/en not_active Abandoned
- 2017-11-03 EP EP17867398.4A patent/EP3535243B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537602A5 (enExample) | ||
| JP2007534695A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| CN114846005A (zh) | Shp2抑制剂及其应用 | |
| JP2017501234A5 (enExample) | ||
| JP2018522823A5 (enExample) | ||
| CA2491895A1 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| JP2020521730A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2002080453A5 (enExample) | ||
| RU2006122519A (ru) | Лечение злокачественных глиом ингибиторами тфр-бэта | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2006515858A5 (enExample) | ||
| NO20071234L (no) | Forbindelser som potensierer glutamatreseptor og anvendelse derav innen medisin | |
| JP2016526576A5 (enExample) | ||
| JP2017531000A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| JP2012512886A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| JP2009543867A5 (enExample) | ||
| RU2013138834A (ru) | N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2 | |
| RU2001125893A (ru) | Производные 3-фенилпиридина и их применение в качестве антагонистов рецептора NK-1 |